vaccin
save
million
human
live
increas
lifespan
pet
reduc
loss
livestock
tradit
vaccin
base
attenu
inactiv
pathogen
case
bacteri
toxin
advanc
molecular
biolog
allow
gener
subunit
vaccin
express
one
pathogen
antigen
induc
protect
immun
respons
viral
bacteri
infect
prevent
suffici
high
titer
neutral
antibodi
elicit
viral
surfac
antigen
glycoprotein
rabi
viru
hemagglutinin
influenza
viru
envelop
protein
human
immunodefici
viru
hiv
pathogen
highli
variabl
therebi
escap
neutral
cellular
immun
respons
form
cell
may
need
elicit
prevent
clinic
symptomat
infect
although
unlik
neutral
antibodi
cell
fail
provid
steril
immun
rapidli
clear
infect
cell
therebi
block
spread
pathogen
ensu
diseas
cell
come
differ
varieti
upon
activ
cell
expand
assum
effector
function
effector
cell
gener
produc
antivir
cytokin
interferon
ifn
gamma
lytic
enzym
perforin
granzym
b
allow
lysi
infect
cell
die
infect
clear
fraction
differenti
effector
central
memori
cell
effector
memori
cell
longerliv
effector
cell
although
number
gradual
declin
circul
peripheri
rapidli
assum
effector
function
although
prolif
capac
limit
central
memori
cell
resid
lymphat
tissu
requir
reactiv
expans
commenc
effector
function
unlik
effector
effector
memori
cell
prolif
capac
high
persist
cytokinedriven
cell
renew
lifespan
individu
central
memori
cell
gener
produc
interleukin
il
ifngamma
lytic
enzym
type
cell
respons
suit
protect
infect
remain
debat
like
depend
type
invad
pathogen
exampl
infect
mice
lymphocyt
choriomening
viru
prevent
central
memori
cell
wherea
chronic
infect
rhesu
macaqu
simian
immunodefici
viru
siv
avert
effector
memori
cell
natur
vaccineinduc
immun
respons
larg
dictat
type
vaccin
carrier
protein
vaccin
viral
vector
vaccin
except
vector
base
cytomegalovirus
cmv
induc
antibodi
includ
neutral
antibodi
foreign
antigen
viral
vector
rapidli
clear
base
poxvirus
ribonucl
acid
rna
virus
exampl
recombin
influenza
rabi
viru
vector
induc
sustain
central
memori
cell
respons
vector
persist
deriv
cmv
adenovirus
maintain
activ
effector
effector
memori
cell
respons
adenovir
vector
persist
low
level
therefor
unlik
cmv
vector
induc
sustain
effectorlik
central
memori
cell
respons
chapter
describ
basic
characterist
adenovirus
vector
base
adenovirus
perform
vaccin
carrier
vaccin
carrier
base
adenovirus
design
retain
abil
replic
render
replicationdefect
upon
delet
gene
segment
need
viral
reproduct
numer
serotyp
adenovirus
isol
human
nonhuman
primat
speci
allow
gener
vector
use
sequenti
primeboost
immun
differ
pathogen
preexist
neutral
antibodi
adenovirus
commonli
found
human
mani
human
serotyp
impair
immunogen
adenovir
vector
circumv
use
vaccin
base
rare
human
serotyp
adenovirus
isol
speci
chimpanze
unless
use
excess
high
dose
adenovir
vector
well
toler
induc
except
potent
sustain
b
cell
respons
foreign
antigen
encod
transgen
adenovir
vector
thu
provid
highli
suitabl
platform
vaccin
carrier
numer
pathogen
adenovirus
member
adenovirida
famili
nonenvelop
virus
doublestrand
genom
rang
kilobas
kb
adenovirus
infect
numer
speci
includ
mammal
bird
even
frog
subdivid
five
genera
depend
target
speci
human
adenovirus
belong
genu
mastadenoviru
divid
seven
famili
ag
distinct
serotyp
chimpanze
adenovirus
vector
gene
transfer
group
within
human
adenovirus
adenoviru
genom
encod
deoxyribonucl
acid
dna
strand
number
earli
late
gene
product
product
three
four
earli
domain
essenti
viral
replic
wherea
product
antiapoptot
allow
viru
escap
immunosurveil
nonessenti
late
gene
encod
icosahedr
viral
capsid
compos
major
protein
hexon
penton
fiber
minor
protein
iiia
vi
viii
ix
hexon
abund
viral
protein
conserv
stalk
head
domain
sever
highli
variabl
loop
serv
target
virusneutr
antibodi
differ
serotyp
adenovirus
famili
mainli
differ
sequenc
variabl
loop
fiber
bind
viral
receptor
adenovirus
coxsacki
adenoviru
receptor
car
wherea
other
bind
coxsacki
adenoviru
receptor
type
membran
protein
express
endotheli
epitheli
cell
express
antigenpres
cell
dendrit
cell
macrophag
inhibitori
complement
receptor
ubiquit
express
also
serv
receptor
measl
viru
human
herp
penton
anchor
fiber
viral
capsid
contain
arginylglycylaspart
acid
rgd
sequenc
bind
integrin
togeth
car
facilit
viru
entri
target
cell
adenovirus
spread
mainli
aerosol
caus
upper
respiratori
diseas
conjunct
tonsil
ear
infect
adenoviru
infect
associ
gastroenter
gener
adenovirus
caus
mild
diseas
although
sever
even
fatal
infect
occur
immunocompromis
individu
rare
occas
healthi
individu
infect
human
shed
adenovirus
fece
day
wherea
nonhuman
primat
chimpanze
shed
virus
long
period
time
adenovirus
persist
low
level
activ
cell
recov
year
infect
lymphat
tissu
live
attenu
vaccin
avail
human
adenovirus
use
unit
state
us
armi
immun
recruit
adenovirus
construct
replicationcompet
replicationdefect
vector
replicationcompet
vector
use
nontarget
speci
fact
replicationdefect
wherea
replicationdefect
vector
replic
degre
cell
transcript
machineri
substitut
delet
gene
product
foreign
sequenc
kb
incorpor
adenoviru
genom
delet
incorpor
longer
sequenc
interfer
packag
viral
rescu
packag
size
increas
delet
domain
onlydelet
adenoviru
vector
remain
replicationcompet
vector
use
vaccin
carrier
delet
render
vector
replicationdefect
delet
gene
product
provid
tran
vector
product
vaccin
vector
use
date
delet
allow
insert
approxim
kb
foreign
sequenc
also
delet
increas
packag
capac
kb
delet
encod
polypeptid
affect
host
cell
prolifer
surviv
provid
nuclear
export
rna
explor
addit
delet
reduc
synthesi
adenovir
protein
turn
may
reduc
stimul
cell
respons
adenovir
antigen
origin
adenoviru
vector
construct
homolog
recombin
packag
cell
line
provid
tran
current
adenovirus
construct
viral
molecular
clone
ligat
transgen
express
cassett
directli
delet
domain
bacteri
clone
upon
linear
transfect
packag
cell
line
viral
rescu
sever
packag
cell
line
avail
hek
cell
carri
gene
region
viru
suit
rescu
vector
well
famili
e
simian
adenovirus
sadv
explor
vaccin
carrier
homolog
recombin
adenoviru
sequenc
within
hek
cell
vector
lead
outgrowth
replicationcompet
virus
problem
sadv
vector
grown
hek
cell
sequenc
differ
region
sadv
virus
prevent
homolog
recombin
cell
offer
altern
carri
domain
reduc
chanc
insert
genom
vector
serotyp
packag
cell
construct
typic
stabl
transfect
cell
line
readili
infect
adenovirus
upon
transfect
packag
cell
recombin
molecular
clone
adenoviru
viral
plaqu
typic
becom
visibl
day
viru
expand
packag
cell
purifi
smallscal
product
vector
purifi
cscl
gradient
centrifug
wherea
largescal
product
chromatograph
separ
suit
viru
particl
vp
content
purifi
vector
determin
spectrophotometri
content
infecti
viru
particl
iu
measur
plaqu
assay
stain
hexon
revers
transcript
polymeras
chain
reaction
method
although
level
transgen
product
express
depend
iu
adenoviru
vector
dose
accord
vp
determin
toxic
prepar
vp
iu
ratio
vari
typic
vector
higher
vp
iu
ratio
tend
perform
poorli
depend
diluent
adenoviru
vector
stabl
sever
day
room
temperatur
sever
month
kept
ice
highli
concentr
adenoviru
vector
lyophil
minim
loss
titer
adenoviru
vector
becom
unstabl
low
ph
may
pose
problem
shipment
dri
ice
co
seep
vial
may
lower
ph
caus
loss
viral
titer
transgen
product
express
adenovir
vector
influenc
number
paramet
hand
vector
express
higher
level
transgen
compar
famili
e
chimpanzeeorigin
adenoviru
vector
chimer
vector
base
bind
chimpanze
vector
shown
express
lower
level
transgen
product
compar
vector
carbind
chimpanze
origin
adenoviru
vector
chimpanzeeorigin
vector
compar
express
wherea
delet
reduc
express
length
transgen
product
also
affect
level
protein
express
longer
transgen
result
reduc
express
promot
regul
transgen
express
shown
influenc
magnitud
kinet
protein
express
orient
transgen
express
cassett
within
significantli
influenc
protein
express
attempt
produc
dualexpress
adenovir
vector
carri
one
cassett
delet
domain
delet
domain
although
abl
gener
stabl
vector
express
transgen
product
vector
share
regulatori
sequenc
within
express
cassett
unstabl
presum
owe
excis
larg
fragment
genom
upon
homolog
recombin
infect
adenovirus
common
human
carri
cell
bind
neutral
antibodi
adenovirus
neutral
antibodi
direct
mainli
adenoviru
hexon
serotypespecif
wherea
antibodi
cell
direct
multipl
antigen
includ
highli
conserv
adenoviru
serotyp
even
famili
highli
crossreact
seroconvers
happen
earli
life
studi
northern
china
show
newborn
compar
toddler
commonli
higher
titer
antibodi
presum
reflect
transmiss
antibodi
mother
infant
age
month
tend
low
titer
steadili
increas
studi
conduct
india
show
neutral
antibodi
viru
slightli
higher
infant
age
month
age
month
titer
steadili
increas
adulthood
studi
conduct
north
america
south
america
subsaharan
africa
southeast
asia
show
low
seropreval
rate
infant
age
month
viru
children
high
preval
rate
antibodi
although
titer
tend
lower
preval
neutral
antibodi
human
adult
vari
depend
serotyp
geograph
region
exampl
neutral
antibodi
common
serotyp
found
individu
resid
us
live
subsaharan
africa
preval
neutral
antibodi
initi
describ
rare
serotyp
low
us
europ
high
african
countri
seropreval
rate
shown
high
africa
low
us
asia
appear
truli
rare
serotyp
less
sera
children
adult
independ
geograph
local
abl
neutral
viru
adenovirus
speciesspecif
human
lack
antibodi
infect
speci
although
depend
serotyp
well
potenti
contact
infect
speci
exampl
describ
antibodi
three
differ
chimpanze
adenovirus
virtual
absent
sera
human
resid
us
could
detect
individu
subsaharan
africa
assum
reflect
close
contact
human
chimpanze
subsaharan
africa
hunt
eat
monkey
common
subsequ
conduct
studi
brazil
found
slightli
enhanc
preval
rate
neutral
antibodi
chimpanze
adenovirus
human
resid
brazil
especi
pronounc
cohort
amazonia
test
new
world
monkey
brazil
show
presenc
neutral
antibodi
chimpanze
adenovirus
nearli
sera
common
marmoset
suggest
spillov
virus
monkey
human
popul
virus
test
sera
differ
region
china
show
low
preval
rate
hightit
antibodi
although
sera
low
titer
found
adult
anoth
studi
measur
preval
rate
neutral
antibodi
caucasian
resid
us
europ
larg
panel
chimpanze
adenovirus
famili
b
c
e
preval
rate
chimpanzeeorigin
adenovirus
titer
greater
sera
except
antibodi
found
sera
one
virus
test
neutral
sera
kenyan
children
sera
high
titer
neutral
antibodi
rare
approxim
wherea
low
titer
common
preexist
neutral
antibodi
adenoviru
caus
rapid
uptak
virion
cell
reticuloendotheli
system
also
lead
activ
complement
specif
neutral
antibodi
prevent
cell
transduct
adenovirus
transcript
translat
transgen
product
result
reduct
vaccin
antigen
diminish
vector
abil
stimul
adapt
immun
respons
paradox
increas
innat
respons
latter
presum
reflect
neutral
antibodi
target
vector
fcreceptorposit
cell
bind
antibodi
preexist
cell
respons
antigen
adenoviru
appear
major
effect
transgen
productspecif
b
cell
respons
effect
preexist
neutral
antibodi
circumv
increas
vaccin
dose
problemat
human
depend
titer
neutral
antibodi
increas
requir
would
like
result
unaccept
toxic
altern
adenoviru
vector
could
combin
anoth
vaccin
modal
dna
vaccin
poxviru
vector
socal
primeboost
regimen
although
known
increas
transgen
productspecif
immun
respons
markedli
also
increas
cost
complex
vaccin
repeat
use
adenoviru
vector
test
augment
immun
respons
rel
ineffect
neutral
antibodi
induc
first
vaccin
dose
impair
uptak
repeat
dose
loss
transduct
presenc
preexist
neutral
antibodi
circumv
coat
virus
polyethylen
glycol
hydrophil
polym
encapsid
microspher
yet
known
whether
approach
also
rescu
adapt
immun
respons
transgen
product
also
possibl
swap
variabl
loop
hexon
common
human
serotyp
rare
human
serotyp
use
straightforward
approach
develop
vector
typic
fail
infect
human
deriv
nonhuman
primat
larg
number
vector
isol
chimpanze
phylogenet
group
within
human
serotyp
molecular
organ
receptor
usag
growth
characterist
similar
human
serotyp
antibodi
human
serotyp
adenovirus
fail
crossreact
chimpanzeederiv
adenovirus
import
alreadi
mention
neutral
antibodi
chimpanze
adenovirus
rare
found
human
preval
rate
antibodi
slightli
increas
africa
presum
owe
closer
contact
infect
chimpanze
chimpanze
adenoviru
vector
thu
highli
suit
vaccin
carrier
use
human
adenovirus
adenoviru
vector
stimul
potent
innat
immun
respons
caus
doselimit
toxic
innat
respons
lead
releas
proinflammatori
cytokin
chemokin
type
ifn
regul
activ
normal
cell
express
secret
macrophag
inflammatori
ifngammainduc
protein
ip
other
typic
trigger
recognit
pathogenassoci
molecular
pattern
cellular
pathogen
recognit
receptor
locat
cell
surfac
endosom
within
cytoplasm
sever
motif
present
adenoviru
vector
recogn
innat
sensor
rgd
motif
penton
activ
nuclear
factorkappa
light
chain
enhanc
activ
b
cell
pathway
trigger
inflammatori
reaction
doublestrand
adenoviru
genom
recogn
tolllik
receptor
tlr
one
endosom
sensor
adenoviru
vector
appear
recogn
addit
tlr
innat
respons
diminish
cell
lack
tir
domaincontain
adapterinduc
ifnbeta
serv
adaptor
adenoviru
genom
activ
retino
acidinduc
anoth
intracellular
sensor
doublestrand
dna
adenovirus
appli
airway
interact
surfact
appear
block
inflammatori
respons
presum
caus
opson
viru
particl
high
dose
adenoviru
vector
activ
complement
system
interact
fiber
knob
blood
factor
ix
bind
protein
interact
increas
inflammatori
respons
adenoviru
vector
sequest
preexist
neutral
antibodi
unknown
reason
interact
increas
inflammatori
respons
vector
potenc
innat
immun
respons
partli
depend
vector
serotyp
exampl
mice
chimpanzeederiv
adenoviru
vector
shown
induc
potent
type
ifn
respons
compar
vector
may
relat
frequenc
cpg
motif
tend
lower
genom
cg
motif
cg
motif
virus
chimpanzeeorigin
adenovirus
approxim
cg
motif
whether
intens
inflammatori
reaction
mice
translat
heighten
toxic
human
remain
test
adenovir
vector
induc
potent
b
cell
respons
capsid
antigen
vector
foreign
transgen
product
latter
allow
use
adenoviru
vector
prophylact
vaccin
infect
prevent
neutral
antibodi
advantag
adenoviru
vector
deliveri
antigen
pathogen
induct
protect
antibodi
respons
numer
interact
innat
sensor
drive
matur
antigenpres
cell
requir
addit
adjuv
adenovir
vector
safe
immunogen
dose
given
multipl
rout
includ
intranas
intramuscular
oral
provid
vector
encapsid
similar
wildtyp
adenovirus
adenoviru
vector
persist
activ
cell
induc
sustain
antibodi
respons
adenovirus
use
host
cell
machineri
posttransl
modif
antigen
viral
antigen
present
nativ
form
unless
structur
depend
cointeract
antigen
compar
magnitud
transgen
productspecif
antibodi
respons
two
chimpanzeederiv
adenoviru
vector
famili
e
member
induc
vector
deriv
famili
c
member
famili
member
vector
express
rabi
viru
glycoprotein
transgen
product
vector
induc
markedli
higher
rabi
virusspecif
antibodi
respons
compar
vector
vector
express
rabi
viru
glycoprotein
licens
immun
wildlif
fox
skunk
neither
speci
support
replic
viru
intend
target
speci
vaccin
replicationdefect
adenoviru
vector
base
simian
serotyp
also
express
rabi
viru
glycoprotein
develop
human
immun
vector
highli
immunogen
induc
protect
titer
rabi
virusneutr
antibodi
nonhuman
primat
singl
low
dose
vp
given
intramuscularli
challeng
antibodi
titer
protect
immun
shown
sustain
least
year
ebola
viru
winter
spring
caus
outbreak
guinea
fall
year
spread
liberia
sierra
leon
isol
case
import
europ
us
world
health
organ
estim
without
improv
intervent
viru
would
continu
spread
potenti
infect
million
individu
other
voic
concern
viral
mutat
may
allow
ebola
viru
transmit
aerosol
even
increas
infect
rate
one
first
ebola
vaccin
underw
test
human
base
vector
express
glycoprotein
zair
sudan
ebola
speci
vaccin
shown
protect
nonhuman
primat
ebola
viru
infect
found
safe
vp
per
dose
human
subject
develop
specif
b
cell
respons
concern
preexist
neutral
antibodi
tend
preval
robust
african
human
popul
second
set
vector
base
chimpanze
serotyp
construct
vaccin
current
undergo
test
human
volunt
provid
vaccin
immunogen
safe
may
use
investig
new
drug
applic
consent
individu
high
risk
contract
viru
one
potenti
setback
ebola
vaccin
although
humor
respons
viral
glycoprotein
develop
rapidli
nonhuman
primat
antibodi
titer
sustain
rather
declin
baselin
within
less
year
could
potenti
address
booster
immun
adenoviru
vector
base
differ
serotyp
unrel
vaccin
prototyp
poxviru
vector
plethora
adenoviru
vector
base
human
simian
serotyp
test
preclin
induct
protect
antibodi
respons
numer
pathogen
includ
hepat
b
viru
dengu
viru
sever
acut
respiratori
syndrom
coronaviru
rotaviru
respiratori
syncyti
viru
rabi
viru
herp
simplex
viru
type
hantaan
viru
influenza
viru
plasmodium
vivax
result
consist
show
vector
induc
potent
antibodi
respons
domin
isotyp
link
type
helper
cell
respons
upon
system
immun
wherea
mucos
inject
also
led
local
immunoglobulin
product
although
neutral
antibodi
primari
correl
protect
pathogen
complex
virus
intracellular
bacteria
protozoa
protect
provid
cellular
immun
respons
achiev
acceler
clearanc
infect
cell
token
chronic
viral
infect
cancer
cell
best
combat
vaccineinduc
cell
respons
adenovirus
acquir
natur
infect
induc
cell
respons
number
viral
protein
cell
found
human
adult
crossreact
differ
adenoviru
serotyp
includ
deriv
chimpanzeeorigin
adenovirus
adenovirusspecif
cell
found
monofunct
larg
belong
memori
subset
contrast
adenovirusspecif
cell
polyfunct
highli
activ
phenotyp
mainli
group
effectoreffector
memori
subset
may
reflect
repeat
exposur
differ
serotyp
adenovirus
intern
reactiv
cell
persist
virus
adenovir
vector
induc
remark
high
transgen
productspecif
cell
respons
least
mice
modest
cell
respons
induct
cell
trigger
crosspresent
antigen
transgen
productspecif
cell
similar
induc
natur
infect
adenoviru
antigen
polyfunct
vector
persist
larg
proport
remain
activ
nevertheless
level
persist
low
adenovirusinduc
cell
part
transit
memori
pool
allow
increas
respons
booster
immun
compar
magnitud
transgen
productspecif
cell
respons
chimpanzeederiv
adenoviru
vector
mice
respons
larg
compar
other
compar
cell
respons
differ
human
chimpanze
serotyp
mice
rhesu
macaqu
speci
human
serotyp
adenovirus
base
famili
c
induc
higher
cell
respons
compar
famili
adenoviru
vector
base
famili
b
use
rather
car
cell
entri
least
immunogen
similar
trend
seen
chimpanzeeorigin
adenoviru
vector
group
c
tend
immunogen
group
e
wherea
one
group
b
viru
least
immunogen
nevertheless
famili
ederiv
vector
immunogen
even
famili
c
vector
larg
number
differ
adenoviru
vector
undergon
preclin
test
cellinduc
vaccin
varieti
pathogen
includ
hepat
c
viru
hcv
trypanosom
cruzii
mycobacterium
tuberculosi
result
show
adenoviru
vector
induc
except
potent
sustain
cell
respons
anim
higher
induc
recombin
vaccin
dna
vaccin
poxviru
vector
cell
respons
induc
adenoviru
vector
enhanc
prime
boostregimen
use
serolog
distinct
adenoviru
vector
vaccin
platform
prime
boost
earlystag
safeti
studi
conduct
sever
humana
well
chimpanzeederiv
adenoviru
vector
express
antigen
tuberculosi
plasmodium
falciparum
ebola
viru
influenza
viru
hcv
result
show
toxic
doserel
unaffect
preexist
neutral
antibodi
vector
high
dose
vp
individu
mainli
experienc
mild
moder
flulik
symptom
fever
myalgia
fatigu
headach
injectionsit
reaction
erythema
local
pain
seen
regardless
vector
dose
repeat
inject
vector
result
decreas
system
reaction
upon
sequenti
immun
vaccin
individu
develop
signific
chang
blood
valu
overal
vaccin
well
toler
analys
vaccineinduc
immun
respons
show
dosedepend
manner
vaccin
recipi
develop
b
cell
transgen
product
also
increas
immun
respons
antigen
adenovir
vector
first
largescal
phase
iib
trial
adenovir
vector
vaccin
step
trial
conduct
merck
vector
express
gag
pol
nef
clade
b
induct
cell
individu
north
south
america
caribbean
australia
high
risk
acquisit
receiv
three
inject
vp
vaccin
placebo
day
week
trial
design
enrol
individu
neutral
antibodi
titer
less
baselin
individu
titer
greater
expect
vaccin
elicit
potent
cell
respons
slightli
attenu
individu
high
titer
preexist
neutral
antibodi
cell
respons
observ
third
vaccin
recipi
trial
stop
prematur
interim
analysi
safeti
monitor
board
show
vaccin
neither
prevent
infect
reduc
viral
load
individu
becam
infect
trial
conduct
parallel
south
africa
phambili
trial
stop
shortli
thereaft
trial
particip
unblind
step
trial
male
vaccin
recipi
mainli
homosexu
engag
highrisk
anal
intercours
increas
rate
acquisit
male
vaccin
recipi
compar
placebo
control
particip
increas
acquisit
link
high
titer
antibodi
baselin
well
lack
circumcis
link
differ
risk
behavior
trend
increas
acquisit
transient
wane
month
seen
phambili
trial
enrol
mainli
heterosexu
men
women
addit
studi
compar
acquisit
rate
particip
trial
base
vaccin
adenovir
vector
show
titer
neutral
antibodi
sever
adenovir
serotyp
increas
acquisit
token
armi
fail
observ
increas
infect
rate
recruit
receiv
live
attenu
adenoviru
vaccin
compar
high
neutral
antibodi
titer
adenoviru
per
se
vaccin
adenoviru
thu
appear
increas
risk
infect
mechan
underli
increas
acquisit
individu
step
trial
studi
extens
remain
unexplain
one
possibl
explor
cell
induc
adenoviru
vector
becom
highli
suscept
infect
cell
also
express
home
marker
gut
mucosa
increas
presenc
target
cell
port
viral
entri
could
explain
increas
acquisit
vaccin
adenovir
vector
nevertheless
explain
increas
acquisit
seen
homosexu
male
high
baselin
titer
neutral
antibodi
next
largescal
efficaci
trial
base
vector
combin
dna
vaccin
prime
prevent
dna
vaccin
express
gag
pol
nef
env
clade
b
c
vector
given
mixtur
express
gagpol
fusion
protein
env
clade
b
c
vector
differ
vector
use
step
trial
addit
delet
inclus
env
vaccin
target
antigen
dna
vaccin
given
three
time
day
week
vector
given
week
studi
conduct
us
enrol
circumcis
male
transgend
women
preexist
neutral
antibodi
titer
high
risk
acquisit
total
particip
enrol
vaccin
arm
particip
enrol
placebo
arm
end
point
prevent
acquisit
lower
viral
load
infect
vaccin
recipi
interim
analysi
show
neither
end
point
would
met
trial
halt
unblind
vaccin
increas
acquisit
rate
vaccin
induc
andor
cell
recipi
antibodi
recipi
antibodi
vaccin
recipi
antibodi
loop
anoth
success
vaccin
efficaci
trial
identifi
correl
protect
viral
acquisit
detect
vaccin
recipi
respons
rate
neutral
antibodi
low
tier
viru
could
neutral
futil
three
vectorbas
vaccin
efficaci
trial
combin
increas
risk
acquisit
subcohort
step
trial
rais
question
use
adenovir
vector
vaccin
platform
gener
initi
earlyphas
immunogen
trial
step
vaccin
shown
breadth
cell
respons
limit
cell
vaccin
individu
recogn
one
four
epitop
limit
epitop
specif
recapitul
small
phase
trial
vaccin
express
env
test
chimpanzeederiv
adenoviru
vector
express
clade
b
gag
rhesu
macaqu
singl
immun
breadth
respons
also
limit
anim
respond
one
two
epitop
boost
serolog
distinct
adenoviru
vector
markedli
increas
breadth
respons
anim
respond
boost
differ
gag
epitop
restrict
epitop
specif
observ
clinic
trial
carri
risk
may
escap
cellular
immunosurveil
thu
potenti
address
primeboost
two
differ
serotyp
adenoviru
vector
vaccin
also
efficaci
step
vaccin
limit
preclin
studi
step
vaccin
protect
rhesu
macaqu
challeng
sivhiv
chimera
provid
protect
stringent
challeng
token
vaccin
fail
protect
rhesu
macaqu
challeng
confer
mhc
class
alleledepend
protect
less
stringent
challeng
other
describ
induct
protect
immun
rhesu
macaqu
immun
adenoviru
vector
human
well
chimpanze
serotyp
use
altern
adenoviru
vector
prophylaxi
continu
explor
clinic
efficaci
trial
explor
carrier
malaria
vaccin
vector
express
p
falciparum
circumsporozoit
protein
apic
membran
fail
protect
control
malaria
infect
wherea
protect
achiev
vaccin
combin
dna
vaccin
prime
similar
level
efficaci
achiev
express
cellinduc
antigen
p
falciparum
follow
modifi
vaccinia
ankara
boost
adenoviru
vectorbas
vaccin
tuberculosi
thu
far
undergon
earlystag
safeti
immunogen
trial
vector
express
shown
induc
cell
individu
naiv
antigen
pathogen
respons
robust
previous
bcg
vaccin
trial
volunt
immunogen
affect
preexist
antibodi
one
phase
trial
test
vector
express
ns
protein
hcv
vector
induc
hcvspecif
cell
respons
crossreact
heterolog
hcv
strain
respons
either
vaccin
polyfunct
sustain
respons
boost
two
vector
use
sequenti
